Vertex Pharmaceuticals ($VRTX) Insider Trading & Smart Money Activity
Vertex Pharmaceuticals Incorporated ($VRTX) has 1 insider trade, 3 congress trades, 4 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($471.41K), net -$471.41K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$471.41K
- Congress trades (12 mo)
- 2
- 13F moves on file
- 4
- Analyst ratings on file
- 2
VRTX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 1 / 0 | 0 / 0 |
| Q2 2026 | 0 | 1 · $471.41K | 0 / 0 | 2 / 0 |
| Q3 2026 | 0 | 0 | 0 / 1 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 1 / 1 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All VRTX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13F | Birch Hill Investment Advisors | Reduced | -4.18K sh | $75.03M | — | ||||||
| 13F | Assenagon Asset Management S.A. | Added | +459.75K sh | $637.47M | Read | ||||||
| Analyst | RBC Capital | Reiterates to Outperform | PT $576 | +1.1% | — | ||||||
| Analyst | UBS | Reiterates to Buy | PT $615 | -4.6% | — | ||||||
| Congress | David J. Taylor | Sale | $1,001 - $15,000 | +1.7% | -3.9% | — | |||||
| Insider | Carmen BozicEVP and CMO | Sell (Open-market sale) 10b5-1 | 1.02K sh | $471.41K | +6.3% | +6.4% | Read | ||||
| 13F | Capital Research Global Investors | Added | +3.81M sh | $9.40B | -5.0% | -1.8% | — | ||||
| 13F | Capital Research Global Investors | Added | +3.81M sh | $10.49B | -5.0% | -1.8% | — | ||||
| Congress | Alan Armstrong | Purchase | $1,001 - $15,000 | +0.3% | -1.6% | +21.5% | — | ||||
| Congress | Tommy Tuberville | Sale | $1,001 - $15,000 | — |
1W / 1M / 6M = how VRTX moved from the trade or filing date.
Insider trading in VRTX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Carmen Bozic | EVP and CMO | 1 | -$471.41K | Jun 18, 2026 |
Members of Congress trading VRTX
Institutions moving VRTX (13F)
Analyst ratings on VRTX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| RBC Capital | Reiterates | Outperform | $570 → $576 | +1.1% | — | |||
| UBS | Reiterates | Buy | $585 → $615 | -4.6% | — |
Frequently asked questions
Are VRTX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $471.41K, a net -$471.41K.
What is the latest insider trade in VRTX?
Carmen Bozic, EVP and CMO filed a sell (open-market sale) of 1.02K sh worth $471.41K on Jun 18, 2026.
Which members of Congress traded VRTX?
3 disclosed trades by David J. Taylor, Alan Armstrong and Tommy Tuberville. The latest was on Aug 26, 2026.
Which institutions changed their VRTX positions?
Recent 13F filers moving the stock include Capital Research Global Investors, Birch Hill Investment Advisors and Assenagon Asset Management S.A..
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.